Efficacy of acetylcholinesterase inhibitors in Alzheimer's disease
2020/10/06 by Gabriella Marucci, Michela Buccioni, Diego Dal Ben +3 · 1,097 citations
Biochemistry, Genetics and Molecular Biology · Chemistry · Medicine · #Acetylcholinesterase #Alzheimer's disease #Chemical synthesis and alkaloids #Chemistry #Cholinergic #Cholinesterase #Cholinesterase and Neurodegenerative Diseases #Dementia #Disease #Donepezil #Galantamine #Internal medicine #Medicine #Memantine #Pharmacology #Phosphodiesterase function and regulation #Rivastigmine #Tacrine
paper · pdf · doi:10.1016/j.neuropharm.2020.108352
published in Neuropharmacology 190, 108352 (Elsevier BV)
openalex publication_date 2020/10/06 · openalex created_date 2025/10/10 · openalex updated_date 2026/08/06
Abstract
Alzheimer's disease (AD), the most common cause of adult-onset dementia is characterized by a progressive decline of cognitive functions accompanied by behavioral manifestations. The main class of drugs currently used for the treatment of AD are acetylcholinesterase/cholinesterase inhibitors (ChE-Is). The first ChE-I licensed for symptomatic treatment of AD was tacrine. The ChE-Is currently available in the market are donepezil, rivastigmine and galantamine as tacrine is no longer in use, due to its hepatotoxicity. According to mechanism of action the ChE-Is are classified as short-acting or reversible agents such as tacrine, donepezil, and galantamine, as intermediate-acting or pseudo-irreversible agent such as rivastigmine. Overall, the efficacy of the three ChE-Is available in the market is similar and the benefit of administration of these compounds is mild and may not be clinically significant. Due to gastrointestinal side effects of these drugs, medicinal chemistry and pharmaceutical delivery studies have investigated solutions to improve the pharmacological activity of these compounds. In spite of the limited activity of ChE-Is, waiting for more effective approaches, these drugs still represent a pharmacotherapeutic resource for the treatment of AD. Other approaches in which ChE-Is were investigated is in their use in combination with other classes of drugs such as cholinergic precursors, N-methyl-d-aspartate (NMDA) receptor antagonists and antioxidant agents. After many years from the introduction in therapy of ChE-Is, the combination with other classes of drugs may represent the chance for a renewed interest of ChE-Is in the treatment of adult-onset dementia disorders.
Cited by
- Current progress in the use of pyrazole-containing compounds for neuroprotection as a strategy to counteract neurodegeneration
- Evaluation of bioactive compounds from Libidibia ferrea (Mart. Ex Tul) LP Queiroz: Antioxidant and antifungal activities, acetylcholinesterase inhibition, and implications in Alzheimer’s disease
- Multi‐Targeting Ligands as Prospective Therapeutics for Alzheimer's Disease, a Prevalent Neurodegenerative Disorder: Mechanistic Insights, Emerging Targets and Drug Discovery Campaigns
- All-in-one colorimetric-photothermal-electrochemical platform based on Fe-doped carbon dots nanozyme with enhanced peroxidase-like activity for flexible analysis of acetylcholinesterase
- Increased anticholinergic medication use in middle‐aged and older autistic adults and its associations with self‐reported memory difficulties and cognitive decline
- Feasibility of integrated transcranial doppler ultrasound-near-infrared spectroscopy to measure cerebral haemodynamics in dementia, delirium, and depression (the VESPAR Project): A pilot study
- Carbamoyl flavonoids as dual inhibitors of acetylcholinesterase and monoacylglycerol lipase: synthesis, in vitro evaluation, and computational studies
- Integrating synthesis, enzyme inhibition and in silico studies: Carbamoyl luteolin derivatives targeting Alzheimer's disease
- Allicin, an Antioxidant and Neuroprotective Agent, Ameliorates Cognitive Impairment. [europepmc]
- Discovery and In Vivo Proof of Concept of a Highly Potent Dual Inhibitor of Soluble Epoxide Hydrolase and Acetylcholinesterase for the Treatment of Alzheimer's Disease. [europepmc]
- Role of Cholinergic Signaling in Alzheimer's Disease. [europepmc]
- A Flavonoid on the Brain: Quercetin as a Potential Therapeutic Agent in Central Nervous System Disorders. [europepmc]
- Neuroprotective Effects of Cholinesterase Inhibitors: Current Scenario in Therapies for Alzheimer's Disease and Future Perspectives. [europepmc]
- Transcranial Direct Current Stimulation Enhances Cognitive Function in Patients with Mild Cognitive Impairment and Early/Mid Alzheimer's Disease: A Systematic Review and Meta-Analysis. [europepmc]
- Acetyl-cholinesterase-inhibitors slow cognitive decline and decrease overall mortality in older patients with dementia. [europepmc]
- Cannabidiol for neurodegenerative disorders: A comprehensive review. [europepmc]
- Effectiveness of KarXT (xanomeline-trospium) for cognitive impairment in schizophrenia: post hoc analyses from a randomised, double-blind, placebo-controlled phase 2 study. [europepmc]
- Multipronged diagnostic and therapeutic strategies for Alzheimer's disease. [europepmc]
- Alzheimer's and Parkinson's disease therapies in the clinic. [europepmc]
- Cognitive impairment in schizophrenia: aetiology, pathophysiology, and treatment. [europepmc]
- Piperidine Derivatives: Recent Advances in Synthesis and Pharmacological Applications. [europepmc]
- Neurotransmitters in Prevention and Treatment of Alzheimer's Disease. [europepmc]
- The neuroprotective effects of targeting key factors of neuronal cell death in neurodegenerative diseases: The role of ER stress, oxidative stress, and neuroinflammation. [europepmc]
- The impact of gamma transcranial alternating current stimulation (tACS) on cognitive and memory processes in patients with mild cognitive impairment or Alzheimer's disease: A literature review. [europepmc]
- New perspectives on the basal forebrain cholinergic system in Alzheimer's disease. [europepmc]
- Bioactive Compounds of the Mediterranean Diet as Nutritional Support to Fight Neurodegenerative Disease. [europepmc]
- Recent Advancement of Medical Patch for Transdermal Drug Delivery. [europepmc]
- An Overview of 1,2,3-triazole-Containing Hybrids and Their Potential Anticholinesterase Activities. [europepmc]
- New strategies of neurodegenerative disease treatment with extracellular vesicles (EVs) derived from mesenchymal stem cells (MSCs). [europepmc]
- Natural compounds as lactate dehydrogenase inhibitors: potential therapeutics for lactate dehydrogenase inhibitors-related diseases. [europepmc]
- Blood-Brain Barrier Breakdown in Alzheimer's Disease: Mechanisms and Targeted Strategies. [europepmc]
- Alzheimer's disease and its treatment-yesterday, today, and tomorrow. [europepmc]
- Multi-Target Drug Design in Alzheimer's Disease Treatment: Emerging Technologies, Advantages, Challenges, and Limitations. [europepmc]
Related